TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Mesoblast Limited ( (AU:MSB) ).
Mesoblast Limited, in collaboration with the NIH-funded Blood and Marrow Transplant Clinical Trials Network, is initiating a pivotal trial for Ryoncil® as a first-line treatment for adults with severe acute graft versus host disease (aGvHD) who are refractory to steroids. This trial aims to address the high non-responsiveness and mortality rates in these patients, offering a potentially life-saving treatment that has shown promising survival rates in previous studies. The trial represents a significant market opportunity, expanding the use of Ryoncil® beyond the pediatric population and addressing a major unmet medical need.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a global leader in developing allogeneic cellular medicines for severe inflammatory diseases. The company specializes in mesenchymal lineage cell therapy technology, which targets severe inflammation by releasing anti-inflammatory factors. Mesoblast’s Ryoncil® is FDA-approved for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients, and the company is expanding its cell therapies for other inflammatory conditions and markets worldwide.
Average Trading Volume: 4,970,266
Technical Sentiment Signal: Buy
Current Market Cap: A$2.9B
For a thorough assessment of MSB stock, go to TipRanks’ Stock Analysis page.